-
-
-
-
-
-
-
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) Appoints Craig Thompson to its Board
-
-
-
-
-
-
-
Esperion Appoints Benjamin O. Looker as General Counsel
-
-
-
-
-
-
-
Esperion Therapeutics (ESPR) and Oberland Capital Announce $200 Million Funding Agreement
-
-
-
-
-
-
-
Pre-Open Movers 12/14: (TEVA) (BAND) (NSDS) Higher; (PIR) (TNTR) (ABM) Lower (more...)
-
-
-
-
-
-
-
Lilly's (LLY) CETP Inhibitor Disappointment Seen as Positive for Esperion (EPSR) and PCSK-9, Says RBC (REGN) (AMGN) (SNY) (MDCO) (MRK)
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/07: (DEPO) (PBMD) (PNK) Higher; (ETRM) (AMD) (SHLM) Lower (more...)
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

